PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia

A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy

The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.

Inclusion Criteria:

• Patients with age between 18 and 70 years
• diagnosis of breast cancer patients who need to receive multi-cycle chemotherapy
• grade III/IV neutropenia after chemotherapy
• KPS score≥70
• life expectancy of at least 3 months
• Written informed consent are acquired

Exclusion Criteria:

• Have accepted any other drug related clinical trial within 4 weeks before anticipated
• uncontrolled infection
• pregnancy
• Other situations that investigators consider as contra-indication for this study